Hepatocellular carcinoma: an update on investigational drugs in phase I and II clinical trials-Reference-Cited by-同舟云学术

Hepatocellular carcinoma: an update on investigational drugs in phase I and II clinical trials

Published:2019-10-12 Issue:11 Volume:28 Page:941-949
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Noonan Anne¹,Pawlik Timothy M.²

Affiliation:

1. Department of Internal Medicine, Division of Medical Oncology, The Ohio State University Wexner Medical Center, The James Comprehensive Cancer Center, Columbus, Ohio, USA

2. Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center, The James Comprehensive Cancer Center, Columbus, Ohio, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543784.2019.1677606

Reference48 articles.

1. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level

2. Temporal trends in liver cancer mortality by educational attainment in the United States, 2000‐2015

3. Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

4. Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study

5. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapeutic strategies in hepatopancreatobiliary cancers;Principles of Immunotherapy Breast and Gastrointestinal Cancers;2025

2. Sorafenib and SIAIS361034, a novel PROTAC degrader of BCL-xL, display synergistic antitumor effects on hepatocellular carcinoma with minimal hepatotoxicity;Biochemical Pharmacology;2024-09

3. The Importance of the Pyrazole Scaffold in the Design of Protein Kinases Inhibitors as Targeted Anticancer Therapies;Molecules;2023-07-12

4. CEUS LI-RADS for diagnosis of hepatocellular carcinoma in individuals without LI-RADS-defined hepatocellular carcinoma risk factors;Cancer Imaging;2023-03-06

5. Locoregional treatments plus immunotherapy in hepatocellular carcinoma: where do we stand?;Future Oncology;2022-05